November 29, 2022 10:57 AM EST

Boehringer Ingelheim buys CD38 drug; Merck bets on machine learning in antibody design

Amber Tong

CD38 may be best known as a target for cancer therapies — notably J&J’s Darzalex and Sanofi’s Sarclisa. But Boehringer Ingelheim believes it has potential in …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Boehringer Ingelheim buys CD38 drug; Merck bets on machine learning in antibody design

Amber Tong

Sign up to read this article for free.

Updated: Amgen obesity shot shows 20% weight loss, but dosing questions hang over readout

Sarepta licenses Arrowhead's RNA-based rare disease pipeline, promising big biobucks

Updated: Roche buys out CAR-T partner Poseida for $1B upfront

Alector says Alzheimer's program targeting microglia fails Phase 2, stock dives

Roche’s TIGIT drug misses last shot at survival endpoint win in Phase 3 lung cancer trial

Trump team asked Warp Speed leader to head NIH, may seek more traditional pick for role

Boehringer In­gel­heim buys CD38 drug; Mer­ck bets on ma­chine learn­ing in an­ti­body de­sign

Amber Tong

Sign up to read this article for free.

more like this

Up­dat­ed: Am­gen obe­si­ty shot shows 20% weight loss, but dos­ing ques­tions hang over read­out

Sarep­ta li­cens­es Ar­row­head­'s RNA-based rare dis­ease pipeline, promis­ing big biobucks

Up­dat­ed: Roche buys out CAR-T part­ner Po­sei­da for $1B up­front

Alec­tor says Alzheimer's pro­gram tar­get­ing mi­croglia fails Phase 2, stock dives

Roche’s TIG­IT drug miss­es last shot at sur­vival end­point win in Phase 3 lung can­cer tri­al

Trump team asked Warp Speed leader to head NIH, may seek more tra­di­tion­al pick for role

Boehringer Ingelheim buys CD38 drug; Merck bets on machine learning in antibody design

Updated: Amgen obesity shot shows 20% weight loss, but dosing questions hang over readout

Sarepta licenses Arrowhead's RNA-based rare disease pipeline, promising big biobucks

Updated: Roche buys out CAR-T partner Poseida for $1B upfront

Alector says Alzheimer's program targeting microglia fails Phase 2, stock dives

Roche’s TIGIT drug misses last shot at survival endpoint win in Phase 3 lung cancer trial

Trump team asked Warp Speed leader to head NIH, may seek more traditional pick for role